Iox-TEVA spray 30 ml. vial

Description

Iox-TEVA Composition
active ingredients: iodized, allantoin;

1 ml of spray contains 85 mg of iodinated povidone 1 mg of allantoin;

excipients: levomenthol, citric acid, sodium, ethanol 96%, propylene glycol, purified water.

Iox-TEVA Dosage form
Oral spray.

Basic physical and chemical properties: transparent or slightly turbid liquid of red-brown color, completely soluble in water.

Iox-TEVA Pharmacotherapeutic group
Medicines used for throat problems. Antiseptics. ATX code R02A A20.

Pharmacodynamics
Iodized povidone is a disinfectant belonging to the group of iodine-containing substances. In contact with the skin or mucous membranes, it releases organic iodine, has a wide spectrum of antimicrobial action due to its direct effect on the proteins of microorganisms. It partially acts bactericidal on gram-positive and gram-negative cocci and bacilli, on some anaerobic bacteria, yeast or sucromycetes, protozoa and some viruses.

The drug also contains allantoin, which has an anti-inflammatory effect, due to which, together with iodinated povidone, the therapeutic effect of the drug is carried out.

Pharmacokinetics
With local application of iodized povidone to intact skin, the absorption of iodine is minimal. When used in the oral cavity, a more pronounced systemic absorption of iodine occurs, as a result of which interference with thyroid functions may occur. Iodine in the body turns into iodides, which accumulate mainly in the thyroid gland and are excreted mainly by the kidneys, as well as in small amounts with feces, saliva, and sweat. Iodides pass through the placental barrier and enter breast milk.

Indications
Disinfection of the oral cavity and pharynx for inflammatory and infectious diseases: tonsillitis, pharyngitis, tonsillopharyngitis, tonsillitis, glossitis and stomatitis; as part of a complex treatment with antibiotics for streptococcal sore throat; the first symptoms of acute respiratory viral infections.

Contraindications
hypersensitivity to the components of the drug;
Dühring’s dermatitis herpetiformis;
hyperthyroidism, adenoma, or thyroid dysfunction;
decompensated heart failure;
impaired renal function;
2 weeks before and after examination or therapy with radioactive iodine.